Prescription Medication for Acid Reflux (GERD)
Start with a single daily dose of a proton pump inhibitor (PPI) for 4-8 weeks as first-line prescription therapy for GERD. 1
Initial Treatment Approach
For patients presenting with typical reflux symptoms (heartburn, acid regurgitation) without alarm features, the evidence strongly supports beginning with FDA-approved single-dose PPI therapy 1. This remains the gold standard prescription medication for GERD management.
Treatment Algorithm:
Week 0-8: Initial Trial
- Prescribe once-daily PPI (omeprazole, lansoprazole, esomeprazole, pantoprazole, or rabeprazole)
- Assess response at 4-8 weeks 1
If Sustained Resolution:
- Wean to the lowest effective dose
- Consider converting to on-demand therapy if symptoms remain controlled 1
- For patients requiring chronic therapy beyond 12 months, perform objective testing to confirm appropriateness of long-term use 1
If Partial or No Response:
- First, verify medication compliance
- Increase to twice-daily PPI (though not FDA-approved for this indication) 1
- Alternatively, switch to a more effective acid suppressive agent 1
- Reassess at 4-8 weeks
When NOT to Use Newer P-CABs as First-Line
Do not use potassium-competitive acid blockers (P-CABs) like vonoprazan as initial therapy for most GERD patients 2. Despite their more potent acid suppression, the 2024 AGA guidance is clear:
- P-CABs should not be first-line for nonerosive reflux disease 2
- P-CABs should not be first-line for mild erosive esophagitis (LA grade A/B) 2
- Higher costs, less availability, insurance authorization requirements, and less long-term safety data outweigh potential benefits when PPIs are effective 2
- P-CABs may be reserved for patients who fail twice-daily PPI therapy 2
The exception: vonoprazan showed superiority to lansoprazole in maintaining healing of erosive esophagitis 3, but cost-effectiveness remains a major barrier in the United States 2.
Adjunctive Prescription Medications (Personalized to Phenotype)
Do not use adjunctive agents empirically—personalize based on symptom pattern 1:
- Nighttime H2-receptor antagonists (ranitidine alternatives like famotidine): Add for persistent nocturnal symptoms despite PPI 1, 4
- Baclofen: For regurgitation-predominant or belch-predominant symptoms (inhibits transient lower esophageal sphincter relaxations) 1, 5
- Prokinetics (metoclopramide): Only when coexistent gastroparesis is documented 1—note that prokinetics have not been proven effective for GERD symptoms alone 5
- Neuromodulators (tricyclic antidepressants, SSRIs): For functional heartburn, reflux hypersensitivity, or visceral hypersensitivity 1, 4, 6
Critical Pitfalls to Avoid
Overprescribing high-dose PPIs: Use the lowest effective dose for the shortest duration 7. Chronic high-dose PPIs carry risks including chronic kidney disease, cardiovascular events, and infections 7.
Continuing PPIs indefinitely without confirmation: If unproven GERD requires PPI beyond 12 months, perform endoscopy with prolonged wireless pH monitoring off PPI to establish appropriateness 1.
Using PPIs for extra-esophageal symptoms without testing: Perform upfront objective reflux testing off medication rather than empiric PPI trial for isolated extra-esophageal symptoms 1.
Ignoring non-responders: If symptoms persist after 4-8 weeks of standard PPI, investigate with endoscopy and pH monitoring rather than indefinitely escalating doses 1.
Evidence Quality Note
The recommendations prioritize the 2024 AGA Clinical Practice Update on P-CABs 2 and the 2022 AGA Clinical Practice Update on personalized GERD management 1, both published in top-tier gastroenterology journals. These guidelines supersede older research and provide the most current, evidence-based approach. The consistent message across all recent guidelines: PPIs remain first-line, P-CABs are reserved for PPI failures, and treatment should be personalized and de-escalated when possible.